Search

Search Constraints

You searched for: Author/Creator Messersmith, Wells

Search Results

1. 388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors. (9th November 2020)

2. 388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors. (9th November 2020)

3. 389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors. (10th December 2020)

4. 389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors. (9th November 2020)

5. 404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC). (10th December 2020)

6. Benchmarks for Academic Oncology Faculty. Issue 3 (March 2021)

7. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). Issue 1 (13th February 2019)

8. Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer. Issue 8 (23rd March 2017)

10. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. (19th January 2016)